Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
← catalyst calendarNCT06473779 · readout in 310 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
326actual
Sites
70
Countries
Argentina, Belgium, Bulgaria +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2027-06-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Asthma
Interventions
- Combination product: Tezepelumab — also filed as TEZSPIRE®
- Combination product: Budesonide/formoterol — also filed as SYMBICORT® pMDI
- Combination product: Albuterol/budesonide (AIRSUPRA®) — also filed as AIRSUPRA®
- Combination product: Mannitol — also filed as ARIDOL®
- Combination product: Salbutamol — also filed as Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
Primary outcome
what the primary-completion date above is the date OFProportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.
measured Week 56
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed